I
iECURE
Mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs
About iECURE
iECURE is a biotechnology startup that leverages disruptive gene-editing technology to treat rare, monogenic liver diseases. The company's innovative approach involves the use of in vivo insertion methods to introduce healthy copies of disease-causing genes into patients, providing long-term, stable expression of these genes. This essentially means that they replace faulty genes with healthy ones in a patient's body, potentially curing the disease.
Read full description
iECURE's primary focus is on "loss of function" liver disorders, which are diseases caused by unhealthy genes with multiple disease-driving mutations. These diseases affect tens of thousands of patients worldwide, and iECURE's mission is to find cures for them.
The company collaborates closely with the University of Pennsylvania's Gene Therapy Program, a leading institution in the field of gene therapy research. This partnership forms the backbone of iECURE's early research and development initiatives.
iECURE's business model revolves around the development and commercialization of its gene-editing therapies. The company recently secured a significant financial boost, raising $65 million to advance its in vivo gene editing programs for the treatment of rare pediatric liver diseases.
Furthermore, the European Commission has granted Orphan Designation for iECURE's lead product candidate GTP-506 for the treatment of Ornithine Transcarbamylase (OTC) Deficiency. This designation is given to drugs intended for the treatment of rare diseases, providing certain benefits and market exclusivity for a period after approval.
The company is led by a management team with extensive experience in biotechnology, rare disease, and gene therapy. The recent appointment of Dr. Gabriel M. Cohn as Chief Medical Officer further strengthens the company's leadership.
At a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Philadelphia, United States
- Employees
- 38
- Open positions
- None listed
- Dealroom signal
- 49.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Spinout, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning iECURE.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Nov 2022 | $65M | $260M | Novo Holdings · OrbiMed · Versant Ventures · LYFE Capital | ↗ |
| SERIES AOther financing | Sep 2021 | $50M | $200M | OrbiMed · Versant Ventures | — |
Growth signals
Latest recorded traffic for iECURE is 5.1K monthly website visits, up 218.8% over the last three months. iECURE's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
OrbiMed
Versant Ventures
Novo Holdings
LYFE Capital
Other known investors1 additional known investor
University of Pennsylvania
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about iECURE on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See iECURE’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.